Glycomine Inc. Secures $115M in Series C Funding to Revolutionize Orphan Drug Development for Rare Metabolic Disorders

Glycomine Inc. is proud to announce a major milestone in its journey to transform the lives of patients with rare metabolic disorders, having successfully raised $115,000,000 in its latest funding round. This significant capital infusion will fuel the groundbreaking development of novel orphan drugs designed specifically for serious, rare disorders of metabolism and protein misfolding—conditions for which there are currently no other therapeutic options. Glycomine’s innovative approach centers on replacement therapies, where substrates, enzymes, and proteins are precisely targeted to vital cellular compartments, offering new hope for conditions that have long been neglected in the pharmaceutical landscape. The funding will be strategically allocated to advance the development and clinical testing of Glycomine’s lead drug candidate, GLM101, a promising substrate replacement therapy in development for phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG). PMM2-CDG is a rare, life-altering disease that has historically presented a critical unmet medical need, and Glycomine’s pioneering therapeutic approach represents a beacon of hope for patients and families affected by this debilitating disorder. In addition to supporting GLM101’s clinical advancement, the new funding will bolster essential research and development initiatives aimed at expanding the company’s pipeline of targeted therapies, enhancing manufacturing capabilities, and accelerating regulatory engagements. This robust financial backing not only reinforces Glycomine’s commitment to addressing urgent therapeutic gaps but also positions the company at the forefront of innovation in the field of orphan drug development, with the ultimate goal of delivering effective, life-changing treatments to those who need them most.